Free Newsletter
How the FDA will spend your fees
Curious how the FDA might spend its PDUFA fees? A new five-year plan shows that FDA will plow the money into post-marketing safety to meet its commitments under the new law passed last fall. The agency would spend the to boost the number of employees looking at new scientific approaches to drug safety, improving adverse event detection and prevention programs, and cutting back on medication errors. Plus, it would invest millions in epidemiology "best practices" and data acquisition. Want more detail? Check out the plan itself on the FDA website.
- see the plan
- check out the story at FDA News
Related Articles:
FDA aims to hire 1,300 by October
FDA: Drugmakers responsible for safety
House passes PDUFA: bill heads to Senate
Panel: Give FDA power to recall
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: